Acer Therapeutics

Acer Therapeutics is a pharmaceutical company focused on acquiring, developing, and commercializing therapies for serious rare diseases and life-threatening conditions with unmet medical needs. In the United States, OLPRUVA (sodium phenylbutyrate) is approved for the treatment of Urea Cycle Disorders (UCDs), including Carbamoyl Phosphate Synthetase (CPS), Ornithine Transcarbamylase (OTC), or Argininosuccinic Acid Synthetase (AS) deficiencies. Acer Therapeutics is also advancing a pipeline of investigational product candidates for the treatment of rare and life-threatening diseases.